ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In addition, ATO combined with TKI showed synergistic anti‐leukaemia effect on chronic myelogenous leukaemia (CML), which is also caused by BCR‐ABL1 8, 9.